MiNK Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019
Net Income	-22.46	-27.99	-30.21	-16.24	-23.8
Depreciation & Amortization	0.2	0.12	0.08	0.06	0.04
Share-Based Compensation	3.86	3.03	1.74	0.09	0.22
Other Operating Activities	2.63	5.98	15.56	7.76	8.6
Operating Cash Flow	-15.76	-18.87	-12.83	-8.34	-14.94
Capital Expenditures	-0.07	-0.25	-0.25	-0.1	-0.43
Investing Cash Flow	-0.07	-0.25	-0.25	-0.1	-0.43
Share Issuance / Repurchase	-0.41	-0.16	39.8	0	0
Debt Issued / Paid	0	0	9.46	11.11	11.44
Financing Cash Flow	-0.41	-0.16	49.26	11.11	11.44
Exchange Rate Effect	-0.03	0.02	0.02	-0.28	-0.12
Net Cash Flow	-16.27	-19.25	36.2	2.39	-4.06
Free Cash Flow	-15.84	-19.12	-13.08	-8.43	-15.37
Free Cash Flow Margin	-	-	-	-	-2228.86%
Free Cash Flow Per Share	-0.46	-0.57	-0.50	-0.35	-1.78

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).